**Author details**

Armand Perret-Liaudet1,2\*, Aline Dorey1 , Yannick Tholance1,3, Benoit Dumont1,2 and Isabelle Quadrio1,2

\*Address all correspondence to: armand.perret-liaudet@chu-lyon.fr

1 Hospices Civils de Lyon, Neurobiologie, Centre Mémoire de Recherche et de Ressources; Hôpitaux de Lyon, Lyon, France

kin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. *Annals of clinical bi‐*

Pre-Analytical and Analytical Critical Factors Influencing the High Variability of the Concentrations Levels of...

http://dx.doi.org/10.5772/55512

189

[8] Hort J., Bartos A., Pirttila T. and Scheltens P. (2010) Use of cerebrospinal fluid bio‐ markers in diagnosis of dementia across Europe. *European Journal of Neurology*, 17,

[9] Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimer's & dementia: the journal of the Alzheimer's Associ‐*

[10] Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsäter H, Anckarsäter R, Andrea‐ sen N, Zetterberg H, Andreasson U, Blennow K (2010) Confounding factors influenc‐ ing amyloid Beta concentration in cerebrospinal fluid. *International journal of*

[11] Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, El‐ moualij B, Schraen S, Moreaud O, Gabelle A, Thouvenot E, Thomas-Anterion C, Tou‐ chon J, Krolak-Salmon P, Kovacs GG, Coudreuse A, Quadrio I, Lehmann S (2012) Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collec‐

[12] Schoonenboom NSM, Mulder C, Vanderstichele H, Van Elk E-J, Kok A, Van Kamp GJ, Scheltens P, Blankenstein M a (2005) Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for

[13] Bateman RJ, Wen G, Morris JC, Holtzman DM (2007) Fluctuations of CSF amyloidbeta levels: implications for a diagnostic and therapeutic biomarker. *Neurology* 68,

[14] Moghekar A, Goh J, Li M, Albert M, O'Brien RJ (2012) Cerebrospinal fluid aβ and tau level fluctuation in an older clinical cohort. *Archives of neurology* 69, 246-50.

[15] Slats D, Claassen JAHR, Spies PE, Borm G, Besse KTC, van Aalst W, Tseng J, Sjögren MJC, Olde Rikkert MGM, Verbeek MM (2012) Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. *Neu‐*

[16] Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. *Clinica*

[17] Chevallier S, Monti M, Michel P, Vollenweider P. (2008 ) Lumbar puncture. *Rev Med*

*Alzheimer's disease*, 2010, Article ID 986310, 11 pages.

tion Tubes. *Journal of Alzheimer's disease: JAD* 30, 1-8.

use in clinical practice. *Clinical chemistry* 51, 189-95.

*ochemistry* 46, 235-40.

90–96

*ation* 8, 65-73.

666-9.

*robiology of aging* 33, 831.e1-9.

*Chimica Acta* 310, 173-186.

*Suisse* 177, 2312-4, 2316-8.

2 Université Lyon 1, CNRS UMR5292, INSERM U1028, Equipe BioRan, Lyon, France

3 Université Lyon 1, CNRS UMR5292, INSERM U1028, Equipe WAKING, Lyon, France
